IRIS - Institutional Research Information System
IRIS è il sistema di gestione integrata dei dati della ricerca (persone, progetti, pubblicazioni, attività) adottato dall'Università degli Studi dell’Insubria.

IRInSubria - Institutional Repository Insubria
IRInSubria raccoglie, conserva, documenta e dissemina le informazioni sulla produzione scientifica dell'Università degli Studi dell’Insubria anche ai fini della valutazione della ricerca.

MORA, BARBARA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.480
EU - Europa 1.076
AS - Asia 734
SA - Sud America 82
AF - Africa 14
OC - Oceania 2
Continente sconosciuto - Info sul continente non disponibili 1
Totale 4.389
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.443
IT - Italia 525
SG - Singapore 295
UA - Ucraina 137
SE - Svezia 104
HK - Hong Kong 102
VN - Vietnam 97
CN - Cina 93
TR - Turchia 92
BR - Brasile 69
IE - Irlanda 67
DE - Germania 63
GB - Regno Unito 56
RU - Federazione Russa 30
FI - Finlandia 28
CA - Canada 26
JP - Giappone 15
IN - India 13
PL - Polonia 12
BD - Bangladesh 9
CZ - Repubblica Ceca 9
MX - Messico 9
ZA - Sudafrica 9
ES - Italia 8
NL - Olanda 8
BE - Belgio 5
FR - Francia 5
LT - Lituania 5
AR - Argentina 4
AT - Austria 4
CL - Cile 4
KE - Kenya 3
TH - Thailandia 3
UZ - Uzbekistan 3
EC - Ecuador 2
GR - Grecia 2
HU - Ungheria 2
KR - Corea 2
MD - Moldavia 2
PK - Pakistan 2
SA - Arabia Saudita 2
VE - Venezuela 2
AE - Emirati Arabi Uniti 1
AL - Albania 1
AU - Australia 1
AZ - Azerbaigian 1
BG - Bulgaria 1
CO - Colombia 1
CR - Costa Rica 1
DZ - Algeria 1
EU - Europa 1
GT - Guatemala 1
ID - Indonesia 1
IQ - Iraq 1
KZ - Kazakistan 1
MY - Malesia 1
NO - Norvegia 1
NZ - Nuova Zelanda 1
RO - Romania 1
TN - Tunisia 1
Totale 4.389
Salva come PNG Salva come JPEG
Città #
Milan 375
Fairfield 323
Ashburn 233
Woodbridge 226
Houston 164
Chandler 150
Seattle 150
Singapore 147
Jacksonville 121
Wilmington 121
Cambridge 116
Ann Arbor 113
Hong Kong 98
Nyköping 77
Dallas 71
Princeton 65
Dublin 64
Izmir 48
Boardman 41
Beijing 38
Dearborn 38
Dong Ket 33
San Diego 31
The Dalles 24
Como 22
Los Angeles 22
Rome 22
London 20
Ogden 20
Redmond 18
New York 16
Helsinki 14
Kocaeli 13
Munich 13
São Paulo 13
Toronto 12
Hanoi 11
Santa Clara 11
Tokyo 11
Warsaw 11
Brno 9
Brooklyn 9
Chicago 9
Johannesburg 9
Frankfurt am Main 8
Poplar 8
Washington 8
Mexico City 7
Orem 7
Varese 7
Amsterdam 6
Atlanta 6
Ho Chi Minh City 6
Montreal 6
San Francisco 6
Ankara 5
Brussels 5
Chennai 5
Denver 5
City of London 4
Columbus 4
Falkenstein 4
Hefei 4
Kilburn 4
Kunming 4
Ottawa 4
Redwood City 4
Cavaria con Premezzo 3
Concord 3
Dhaka 3
Gavirate 3
Jackson 3
Manchester 3
Nairobi 3
Nanchang 3
Nanjing 3
Norwalk 3
Nuremberg 3
Rio de Janeiro 3
Salt Lake City 3
San Jose 3
Stockholm 3
Tashkent 3
Alvorada 2
Belo Horizonte 2
Boston 2
Busto Arsizio 2
Charlotte 2
Cleveland 2
Espoo 2
Ha Long 2
Joinville 2
Juiz de Fora 2
Miami 2
Mountain View 2
Mumbai 2
Phoenix 2
Piombino 2
Praia Grande 2
Prescot 2
Totale 3.361
Salva come PNG Salva come JPEG
Nome #
Impact of ruxolitinib on the natural history of primary myelofibrosis: a comparison of the DIPSS and the COMFORT-2 cohorts 219
A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis 216
Looking for CALR mutations in familial myeloproliferative neoplasms 202
A new acute myeloid leukemia case with STAT5B-RARA gene fusion due to 17q21.2 interstitial deletion 200
Involvement of MAF/SPP1 axis in the development of bone marrow fibrosis in PMF patients 187
It is time to change thrombosis risk assessment for PV and ET? 179
Developments in diagnosis and treatment of essential thrombocythemia 179
Driver mutations' effect in secondary myelofibrosis: An international multicenter study based on 781 patients 176
Gender effect on phenotype and genotype in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis: results from the MYSEC project 176
Impact of bone marrow fibrosis grade in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: A study of the MYSEC group 175
New molecular genetics in the diagnosis and treatment of myeloproliferative neoplasms 162
Immunogenicity of anti-SARS-CoV-2 Comirnaty vaccine in patients with lymphomas and myeloma who underwent autologous stem cell transplantation 152
Prognostication in myelofi-brosis 136
Post-ET and Post-PV Myelofibrosis: Updates on a Distinct Prognosis from Primary Myelofibrosis 136
Validation and further potentialities of the novel AWM score for progression risk stratification in patients with asymptomatic Waldenström macroglobulinemia 133
Therapy of polycythemia vera: Is it time to change? 128
Value of cytogenetic abnormalities in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: A study of the MYSEC project 127
Polycythemia vera: From new, modified diagnostic criteria to new therapeutic approaches 112
Phenotype variability of patients with post polycythemia vera and post essential thrombocythemia myelofibrosis is associated with the time to progression from polycythemia vera and essential thrombocythemia 110
Immunogenicity and clinical efficacy of anti-SARS-CoV-2 vaccination in patients with hematological malignancies: results of a prospective cohort study of 365 patients 104
Second primary malignancies in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 2233 patients 101
A prognostic model to predict survival after 6 months of ruxolitinib in patients with myelofibrosis 100
Recurrence of immune thrombocytopenia at the time of SARS-CoV-2 infection 97
MYD88L265P Detection in IgM Monoclonal Gammopathies: Methodological Considerations for Routine Implementation 97
Increased plasma levels of lncrnas linc01268, gas5 and malat1 correlate with negative prognostic factors in myelofibrosis 90
Is there a gender effect in polycythemia vera? 88
Impact of ruxolitinib on survival of patients with myelofibrosis in the real world: Update of the ERNEST Study 83
Direct-acting antivirals in relapsed or refractory hepatitis C virus-associated diffuse large B-cell lymphoma 82
Molecular profiling and risk classification of patients with myeloproliferative neoplasms and splanchnic vein thromboses 81
Gene expression profile correlates with molecular and clinical features in patients with myelofibrosis 81
COVID-19 elicits an impaired antibody response against SARS-CoV-2 in patients with haematological malignancies 79
Stem cell mobilization after bendamustine in indolent lymphomas: a multicenter study on behalf of the Fondazione Italiana Linfomi 75
The future of research in hematology: Integration of conventional studies with real-world data and artificial intelligence 68
Second primary malignancies in ruxolitinib-treated myelofibrosis: Real-world evidence from 219 consecutive patients 63
Platelet count predicts driver mutations’ co-occurrence in low JAK2 mutated essential thrombocythemia and myelofibrosis 54
Direct-acting antivirals in hepatitis C virus-positive mantle cell lymphomas 41
Totale 4.489
Salva come PNG Salva come JPEG
Categoria #
all - tutte 21.489
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 21.489
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021436 0 0 0 0 0 65 42 63 75 56 62 73
2021/2022331 50 16 2 15 11 22 16 21 26 87 19 46
2022/2023473 33 13 75 43 36 102 2 56 75 13 9 16
2023/2024618 91 94 92 115 133 40 7 4 25 2 5 10
2024/2025555 15 3 79 43 23 25 18 54 84 49 42 120
2025/2026649 106 87 70 229 132 25 0 0 0 0 0 0
Totale 4.489